Subprotocol Z1F of the NCI-MATCH trial (phase II, NCT05490771) evaluated copanlisib, in patients with PIK3CA-mutated cancers, enrolling 35 patients, with 25 included in the primary efficacy analysis. The gene discussed is PIK3CA; the disease is cancer.